According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best drug store stocks to buy right now are:
1. High Tide (NASDAQ:HITI)
High Tide (NASDAQ:HITI) is the #1 top pharmaceutical retailer stock out of 7 with a Zen Rating of C. Stocks with a rating of C have had an average return of +7.53% per year.
Learn more.
The Component Grade breakdown for High Tide (NASDAQ:HITI) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: D, Financials: C, and AI: C.
High Tide (NASDAQ:HITI) has a Due Diligence Score of 40, which is 18 points higher than the pharmaceutical retailer industry average of 22.
HITI passed 13 out of 33 due diligence checks and has average fundamentals. High Tide has seen its stock return 36.41% over the past year, overperforming other pharmaceutical retailer stocks by 60 percentage points.
High Tide has an average 1 year
price target of $5.00, an upside of 87.97% from High Tide's current stock price of $2.66.
High Tide stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering High Tide, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Wellgistics Health (NASDAQ:WGRX)
The Component Grade breakdown for Wellgistics Health (NASDAQ:WGRX) is: Value: F, Growth: C, Momentum: C, Sentiment: C, Safety: D, Financials: F, and AI: C.
Wellgistics Health (NASDAQ:WGRX) has a Due Diligence Score of 11, which is -11 points lower than the pharmaceutical retailer industry average of 22.
WGRX passed 3 out of 33 due diligence checks and has weak fundamentals.
3. Scienture Holdings (NASDAQ:SCNX)
The Component Grade breakdown for Scienture Holdings (NASDAQ:SCNX) is: Value: F, Growth: C, Momentum: D, Sentiment: C, Safety: F, Financials: D, and AI: F.
Scienture Holdings (NASDAQ:SCNX) has a Due Diligence Score of 10, which is -12 points lower than the pharmaceutical retailer industry average of 22.
SCNX passed 3 out of 33 due diligence checks and has weak fundamentals. Scienture Holdings has seen its stock lose -83.24% over the past year, underperforming other pharmaceutical retailer stocks by -60 percentage points.